Dave emails to add something I missed in my column this week discussing the recent weakness in BioDelivery Sciences ( BDSI) and its cancer pain drug Onsolis.

"Keep in mind that you failed to turn up that one of the reasons for the sell off since June 15th is that Elliott Associates, which had 3.2 million shares have decided to sell down their stake," writes Dave. "They have done this bit by bit over five and half week now, and as of last week only had 265,000 shares left."


Last, I was pleasantly surprised to hear from "Big % Gains Ltd." last week after my discussion of Cell Therapeutics' ( CTIC) recent fund-raising effort.

"Today you were fair and balanced. That's all I ask."

A Cell Therapeutics' investor is happy with me? We live in strange times, indeed!

-- Reported by Adam Feuerstein in Boston
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Goodbye

Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio